DURECT (NASDAQ:DRRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of DURECT (NASDAQ:DRRX) in a report published on Monday morning. The brokerage issued a sell rating on the specialty pharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating on shares of DURECT in a research note on Thursday, November 14th.

DURECT Trading Down 7.2 %

Shares of DRRX opened at $0.81 on Monday. DURECT has a 12 month low of $0.52 and a 12 month high of $1.88. The firm has a fifty day simple moving average of $0.97 and a 200 day simple moving average of $1.25. The stock has a market capitalization of $25.05 million, a price-to-earnings ratio of -1.32 and a beta of 0.94.

Hedge Funds Weigh In On DURECT

An institutional investor recently raised its position in DURECT stock. Geode Capital Management LLC grew its holdings in shares of DURECT Co. (NASDAQ:DRRX) by 4.8% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 319,905 shares of the specialty pharmaceutical company’s stock after acquiring an additional 14,658 shares during the period. Geode Capital Management LLC owned about 1.03% of DURECT worth $429,000 as of its most recent SEC filing. Institutional investors and hedge funds own 28.03% of the company’s stock.

DURECT Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis.